Business Context and Reporting Period
This Form 8-K was filed by Aileron Therapeutics, Inc. (trading symbol: ALRN) on August 21, 2024, reporting events from its 2024 Annual Meeting of Stockholders held on August 20, 2024. The company is incorporated in Delaware and operates on The Nasdaq Capital Market. Note: The request metadata referenced "Rein Therapeutics, Inc.," but the filing text explicitly identifies the registrant as Aileron Therapeutics, Inc.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Voting Results
The filing details the outcomes of three matters submitted to a vote of security holders:
- Election of Directors: Stockholders elected Brian Windsor, Ph.D., and Alan A. Musso as Class I directors for a three-year term expiring in 2027.
- Brian Windsor, Ph.D.: 7,828,121 votes For; 24,847 Withheld; 3,442,389 Broker Non-Votes.
- Alan A. Musso: 7,828,044 votes For; 24,924 Withheld; 3,442,389 Broker Non-Votes.
- Executive Compensation: Stockholders approved, on a non-binding advisory basis, the compensation of named executive officers.
- 7,326,953 votes For; 109,458 Against; 416,557 Abstain; 3,442,389 Broker Non-Votes.
- Ratification of Auditors: Stockholders ratified the appointment of Marcum LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- 10,817,251 votes For; 61,696 Against; 416,410 Abstain.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors beyond the standard disclosures inherent in an 8-K. No unusual items or contingencies were reported in this document.
Investor Verification Checklist
- Verify the correct registrant name is Aileron Therapeutics, Inc., not Rein Therapeutics, Inc.
- Confirm the tenure of the newly elected Class I directors (Brian Windsor and Alan Musso) through the 2027 Annual Meeting.
- Review the significant number of broker non-votes (3,442,389) across all proposals, which may indicate shares held in street name where brokers lacked discretionary voting authority.
- Check subsequent filings for the full 2024 financial results, as this 8-K contains no financial data.